FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213096313> ?p ?o ?g. }

• W4213096313 endingPage "19" @default.
• W4213096313 startingPage "19" @default.
• W4213096313 abstract "19 Background: Addition of abiraterone plus prednisone (AAP) to androgen deprivation therapy (ADT) with or without docetaxel (D) improved overall survival in men with de novo metastatic castration sensitive prostate cancer in PEACE-1 trial. An analysis of bone mineral density (BMD) was planned by an amendment in the last randomized patients to assess whether addition of AAP increases bone loss. Methods: Patients (pts) were randomized to receive either ADT + D + AAP or ADT + D (and also randomized for radiotherapy given to the prostate). BMD (g/cm 2 ) of the lumbar spine (L), femoral neck (F) and total hip (H) were measured by dual x-ray absorptiometry at baseline, M6, M12 and M24 in both arms. Mean percent change in BMD values from baseline to the different time points were calculated. T-Scores were also assessed. Results: Among the 210 pts with BMD data, 182 (87%) had available data at baseline, 109 (52%) at M6, 94 (45%) at M12, and 109 (52%) at M24: 97 pts were treated with AAP and 98 without. In both arms, the median age was 65 years and 69 pts (71%) were ECOG PS 0. Median body mass index (BMI) was 25.6 and 26.5 kg/m 2 in pts treated with or without AAP, respectively. BMD, T score and mean percent change in BMD values are summarized in the Table. Conclusions: This is the first prospective assessment of BMD in a randomized trial, according to an experimental treatment with AAP. Despite a bone loss increase in both arms over time, addition of AAP to ADT+D was associated with no or modest difference in bone loss during the first 2 years, compared to ADT+D. Data including fractures will be presented. Main limitations include the difficulty to reliably assess BMD in men with bone metastases, the limited sample size and the short follow-up (i.e. 2 years). Clinical trial information: NCT01957436. [Table: see text]" @default.
• W4213096313 created "2022-02-24" @default.
• W4213096313 creator A5001456598 @default.
• W4213096313 creator A5003798935 @default.
• W4213096313 creator A5006249276 @default.
• W4213096313 creator A5007779528 @default.
• W4213096313 creator A5011506675 @default.
• W4213096313 creator A5012288965 @default.
• W4213096313 creator A5012856220 @default.
• W4213096313 creator A5015037372 @default.
• W4213096313 creator A5020692060 @default.
• W4213096313 creator A5023596460 @default.
• W4213096313 creator A5027911519 @default.
• W4213096313 creator A5031868807 @default.
• W4213096313 creator A5036085547 @default.
• W4213096313 creator A5063584845 @default.
• W4213096313 creator A5067036952 @default.
• W4213096313 creator A5068223483 @default.
• W4213096313 creator A5071204291 @default.
• W4213096313 creator A5074178269 @default.
• W4213096313 creator A5081519723 @default.
• W4213096313 creator A5089019258 @default.
• W4213096313 date "2022-02-20" @default.
• W4213096313 modified "2023-10-17" @default.
• W4213096313 title "Bone mineral density in men with <i>de novo</i> metastatic castration-sensitive prostate cancer treated with or without abiraterone plus prednisone in the PEACE-1 phase 3 trial." @default.
• W4213096313 doi "https://doi.org/10.1200/jco.2022.40.6_suppl.019" @default.
• W4213096313 hasPublicationYear "2022" @default.
• W4213096313 type Work @default.
• W4213096313 citedByCount "1" @default.
• W4213096313 countsByYear W42130963132023 @default.
• W4213096313 crossrefType "journal-article" @default.
• W4213096313 hasAuthorship W4213096313A5001456598 @default.
• W4213096313 hasAuthorship W4213096313A5003798935 @default.
• W4213096313 hasAuthorship W4213096313A5006249276 @default.
• W4213096313 hasAuthorship W4213096313A5007779528 @default.
• W4213096313 hasAuthorship W4213096313A5011506675 @default.
• W4213096313 hasAuthorship W4213096313A5012288965 @default.
• W4213096313 hasAuthorship W4213096313A5012856220 @default.
• W4213096313 hasAuthorship W4213096313A5015037372 @default.
• W4213096313 hasAuthorship W4213096313A5020692060 @default.
• W4213096313 hasAuthorship W4213096313A5023596460 @default.
• W4213096313 hasAuthorship W4213096313A5027911519 @default.
• W4213096313 hasAuthorship W4213096313A5031868807 @default.
• W4213096313 hasAuthorship W4213096313A5036085547 @default.
• W4213096313 hasAuthorship W4213096313A5063584845 @default.
• W4213096313 hasAuthorship W4213096313A5067036952 @default.
• W4213096313 hasAuthorship W4213096313A5068223483 @default.
• W4213096313 hasAuthorship W4213096313A5071204291 @default.
• W4213096313 hasAuthorship W4213096313A5074178269 @default.
• W4213096313 hasAuthorship W4213096313A5081519723 @default.
• W4213096313 hasAuthorship W4213096313A5089019258 @default.
• W4213096313 hasConcept C121608353 @default.
• W4213096313 hasConcept C126322002 @default.
• W4213096313 hasConcept C126894567 @default.
• W4213096313 hasConcept C141071460 @default.
• W4213096313 hasConcept C168563851 @default.
• W4213096313 hasConcept C2775832370 @default.
• W4213096313 hasConcept C2775854910 @default.
• W4213096313 hasConcept C2776541429 @default.
• W4213096313 hasConcept C2776886416 @default.
• W4213096313 hasConcept C2777899217 @default.
• W4213096313 hasConcept C2778720950 @default.
• W4213096313 hasConcept C2780192828 @default.
• W4213096313 hasConcept C2781190966 @default.
• W4213096313 hasConcept C71924100 @default.
• W4213096313 hasConceptScore W4213096313C121608353 @default.
• W4213096313 hasConceptScore W4213096313C126322002 @default.
• W4213096313 hasConceptScore W4213096313C126894567 @default.
• W4213096313 hasConceptScore W4213096313C141071460 @default.
• W4213096313 hasConceptScore W4213096313C168563851 @default.
• W4213096313 hasConceptScore W4213096313C2775832370 @default.
• W4213096313 hasConceptScore W4213096313C2775854910 @default.
• W4213096313 hasConceptScore W4213096313C2776541429 @default.
• W4213096313 hasConceptScore W4213096313C2776886416 @default.
• W4213096313 hasConceptScore W4213096313C2777899217 @default.
• W4213096313 hasConceptScore W4213096313C2778720950 @default.
• W4213096313 hasConceptScore W4213096313C2780192828 @default.
• W4213096313 hasConceptScore W4213096313C2781190966 @default.
• W4213096313 hasConceptScore W4213096313C71924100 @default.
• W4213096313 hasIssue "6_suppl" @default.
• W4213096313 hasLocation W42130963131 @default.
• W4213096313 hasOpenAccess W4213096313 @default.
• W4213096313 hasPrimaryLocation W42130963131 @default.
• W4213096313 hasRelatedWork W1977154570 @default.
• W4213096313 hasRelatedWork W2111028754 @default.
• W4213096313 hasRelatedWork W2158933186 @default.
• W4213096313 hasRelatedWork W2591232777 @default.
• W4213096313 hasRelatedWork W2931451269 @default.
• W4213096313 hasRelatedWork W2950753006 @default.
• W4213096313 hasRelatedWork W2970590492 @default.
• W4213096313 hasRelatedWork W3030762477 @default.
• W4213096313 hasRelatedWork W4206312281 @default.
• W4213096313 hasRelatedWork W4223536538 @default.
• W4213096313 hasVolume "40" @default.
• W4213096313 isParatext "false" @default.
• W4213096313 isRetracted "false" @default.
• W4213096313 workType "article" @default.